{[ promptMessage ]}

Bookmark it

{[ promptMessage ]}

Chapter_14_Summary_Outline

Chapter_14_Summary_Outline - Chapter 14 Schizophrenia and...

Info iconThis preview shows pages 1–3. Sign up to view the full content.

View Full Document Right Arrow Icon
Chapter 14: Schizophrenia and Other Psychotic Disorders Overview/Summary Schizophrenia is the most severe form of mental illness. It is characterized by impairments in many domains and affects approximately one percent of the population. Characteristic symptoms of schizophrenia include hallucinations, delusions, disorganized speech, disorganized and catatonic behavior, and so- called “negative” symptoms. Most cases of schizophrenia begin in late adolescence or early adulthood. The disorder begins earlier in men than it does in women. Overall, the clinical symptoms of schizophrenia tend to be more severe in men than women. Women also have a better long-term outcome. Genetic factors are clearly implicated in schizophrenia. Having a relative with the disorder significantly raises a person’s risk of developing schizophrenia. Other factors that have been implicated in the development of schizophrenia include prenatal exposure to the influenza virus, early nutritional deficiencies, and perinatal birth complications. Current thinking about schizophrenia emphasizes the interplay between genetic and environmental factors. Even though schizophrenia begins in early adulthood, researchers believe that it is a neurodevelopmental disorder. A “silent lesion” in the brain is thought to lie dormant until normal developmental changes occur and expose the problems that result from this brain abnormality. Many brain areas are abnormal in schizophrenia, although abnormalities are not found in all patients. Brain abnormalities that have been found include decreased brain volume, enlarged ventricles, frontal lobe dysfunction, reduced volume of the thalamus, and abnormalities in temporal lobe areas such as the hippocampus. The most important neurotransmitters implicated in schizophrenia are dopamine and glutamate. Patients with schizophrenia have many problems in aspects of neurocognitive functioning. They show a variety of attentional deficits (e.g., poor “P50” suppression and deficits on the Continuous Performance Test). They also show eye-tracking dysfunctions. Patients with schizophrenia are more likely to relapse if their relatives are high in expressed emotion (EE). High EE environments may be stressful to patients and may trigger biological changes that cause dysregulations in the dopamine and glutamate systems. This could lead to a return of symptoms. Interestingly, both being raised in an urban environment and immigration have been shown to increase the risk of schizophrenia, perhaps through the effect of stress. For many patients, schizophrenia is a chronic disorder requiring long-term treatment or institutionalization. However, with therapy and medications, about thirty-eight percent of patients show a reasonable recovery. Only about sixteen percent of patients recover to the extent that they no longer need treatment.
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full Document Right Arrow Icon
Patients with schizophrenia are usually treated with antipsychotic (neuroleptic) medications. Second-generation antipsychotics cause fewer extrapyramidal
Background image of page 2
Image of page 3
This is the end of the preview. Sign up to access the rest of the document.

{[ snackBarMessage ]}

Page1 / 10

Chapter_14_Summary_Outline - Chapter 14 Schizophrenia and...

This preview shows document pages 1 - 3. Sign up to view the full document.

View Full Document Right Arrow Icon bookmark
Ask a homework question - tutors are online